Ophthalmology vs Rare Disease — Deal Terms Comparison

Ophthalmology Median Upfront

$768M

Total: $3.6B

Rare Disease Median Upfront

$285M

Total: $1.6B

Ophthalmology Royalties

10.2%-20.4%

Tiered to 24.4%

Rare Disease Royalties

7.8%-15.6%

Tiered to 19.6%

Model Your Deal

Market Analysis

Ophthalmology and Rare Disease represent distinct licensing landscapes with different risk-reward dynamics. Phase 2 ophthalmology deals carry a median total deal value of $3.6B with $768M upfront, compared to $1.6B total value and $285M upfront for rare disease. The differences reflect divergent clinical development timelines, regulatory pathways, and addressable market sizes.

Deal structures differ across therapeutic areas. Ophthalmology deals allocate 21% to upfront and 79% to milestones, while Rare Disease deals split 18%/82%. Development milestones are $569M for ophthalmology versus $283M for rare disease, reflecting the different clinical trial designs and approval standards in each area.

Customize these benchmarks for your asset

Adjust phase, modality, competitive position, and 10+ other parameters.

Open Calculator

Frequently Asked Questions

How do ophthalmology and rare disease deal terms compare?

Ophthalmology Phase 2 deals average $3.6B total value ($768M upfront), while Rare Disease deals average $1.6B ($285M upfront). The differences are driven by addressable market size, clinical development complexity, and regulatory pathway characteristics.

Which therapeutic area commands higher royalty rates: Ophthalmology or Rare Disease?

Ophthalmology base royalties range from 10.2% to 20.4%, while Rare Disease royalties range from 7.8% to 15.6%. Royalty rates reflect pricing power, competitive dynamics, and patent protection characteristics specific to each therapeutic area.

What drives the deal value differences between ophthalmology and rare disease?

Key factors include addressable patient population size, clinical trial costs and timelines, regulatory pathway complexity, pricing and reimbursement dynamics, and competitive landscape density. Ophthalmology and Rare Disease each have unique value drivers that shape deal economics.

PRO

Full Benchmark Analysis

Complete deal term ranges, comparable transactions, and negotiation insights.

Start 7-Day Free Trial

$299/mo after trial · Cancel anytime

Related Benchmarks

Ready to Calculate Your Deal Terms?

Get instant, customized benchmarks based on real market data from 1,600+ biopharma licensing deals.

Start Calculating

For Funds & Advisors

Need the full deal landscape?

The Deal Intelligence Brief covers every modality and deal structure for this indication — 52 deal calculations, AI strategic narrative, comparable transactions, partner matching, and white-label branding. Delivered in 24 hours.

Configure Brief — $2,500All-inclusive · White-label · Walkthrough included